IGM Biosciences Inc
IGMS1.390USD
-0.070-4.79%
收盘 04/23, 16:00（美东）报价延迟15分钟
82.91M总市值
亏损市盈率 TTM
关于 IGM Biosciences Inc 公司
IGM Biosciences, Inc. 是一家临床阶段的生物技术公司。该公司致力于开发和提供一类新药，用于治疗癌症和自身免疫性和炎症性疾病患者。该公司的临床和临床前资产管线基于 IgM 抗体，该抗体具有 10 个结合位点，而传统 IgG 抗体只有两个结合位点。该公司还专注于创造、开发、制造和商业化针对肿瘤学和免疫学和炎症靶点的 IgM 抗体激动剂。该公司的开发项目包括 Aplitabart、Imvotamab 和 IGM-2644。Aplitabart 是一种靶向死亡受体 5 (DR5) 蛋白的 IgM 抗体，正在多项 I 期联合试验中评估其用于治疗结直肠癌的效果。Imvotamab 是一种靶向 CD20 和 CD3 蛋白的双特异性 T 细胞接合 IgM 抗体。IGM-2644 是一种靶向 CD38 和 CD3 蛋白的双特异性 T 细胞接合 IgM 抗体。
公司简介
公司代码IGMS
公司名称IGM Biosciences Inc
上市日期Sep 18, 2019
成立日期2012
CEODr. Mary Beth Harler, M.D.
员工数量149
证券类型Ordinary Share
年结日Sep 18
公司地址325 E Middlefield Rd
城市MOUNTAIN VIEW
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编94043-4003
电话16509657873
网址https://igmbio.com/
公司代码IGMS
上市日期Sep 18, 2019
成立日期2012
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Mary Beth Harler, M.D.
Dr. Mary Beth Harler, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
339.70K
-2.11%
Mr. Misbah Tahir, CPA
Mr. Misbah Tahir, CPA
Chief Financial Officer
Chief Financial Officer
180.32K
-3.91%
Dr. William Strohl, Ph.D.
Dr. William Strohl, Ph.D.
Independent Director
Independent Director
125.00K
--
Mr. Jakob Haldor Topsoe
Mr. Jakob Haldor Topsoe
Independent Director
Independent Director
90.88K
+0.92%
Ms. Christina Teng Topsoe
Ms. Christina Teng Topsoe
Independent Director
Independent Director
62.75K
+2.09%
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Independent Director
Independent Director
--
--
Dr. Elizabeth H. Z. Thompson, Ph.D.
Dr. Elizabeth H. Z. Thompson, Ph.D.
Independent Director
Independent Director
--
--
Dr. Lisa L. Decker, Ph.D.
Dr. Lisa L. Decker, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Dr. M. Kathleen Behrens, Ph.D.
Dr. M. Kathleen Behrens, Ph.D.
Independent Director
Independent Director
--
--
Mr. Michael Lee
Mr. Michael Lee
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Mary Beth Harler, M.D.
Dr. Mary Beth Harler, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
339.70K
-2.11%
Mr. Misbah Tahir, CPA
Mr. Misbah Tahir, CPA
Chief Financial Officer
Chief Financial Officer
180.32K
-3.91%
Dr. William Strohl, Ph.D.
Dr. William Strohl, Ph.D.
Independent Director
Independent Director
125.00K
--
Mr. Jakob Haldor Topsoe
Mr. Jakob Haldor Topsoe
Independent Director
Independent Director
90.88K
+0.92%
Ms. Christina Teng Topsoe
Ms. Christina Teng Topsoe
Independent Director
Independent Director
62.75K
+2.09%
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Independent Director
Independent Director
--
--
收入明细
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
暂无数据
地区USD
名称
营收
占比
United States
2.68M
0.00%
业务
地区
暂无数据
股东统计
更新时间: 4月2日 周三
更新时间: 4月2日 周三
持股股东
股东类型
持股股东
股东统计
占比
Baker Bros. Advisors LP
11.91%
T. Rowe Price Associates, Inc.
10.18%
Invus Public Equities Advisors, LLC
9.68%
Redmile Group, LLC
8.58%
Sanofi
4.18%
Other
55.45%
持股股东
股东统计
占比
Baker Bros. Advisors LP
11.91%
T. Rowe Price Associates, Inc.
10.18%
Invus Public Equities Advisors, LLC
9.68%
Redmile Group, LLC
8.58%
Sanofi
4.18%
Other
55.45%
股东类型
股东统计
占比
Investment Advisor
27.23%
Investment Advisor/Hedge Fund
15.31%
Hedge Fund
13.66%
Individual Investor
5.49%
Corporation
4.18%
Research Firm
3.12%
Bank and Trust
0.04%
Pension Fund
0.02%
Other
30.94%
机构持股
更新时间: 3月3日 周一
更新时间: 3月3日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q1
247
34.19M
99.42%
-4.51M
2024Q4
261
34.20M
100.37%
-4.65M
2024Q3
262
33.88M
99.73%
-5.05M
2024Q2
269
34.16M
101.16%
-4.19M
2024Q1
277
34.60M
103.20%
-3.37M
2023Q4
277
33.51M
100.77%
-4.17M
2023Q3
286
34.23M
103.22%
-3.29M
2023Q2
291
34.31M
107.60%
+1.63M
2023Q1
295
29.58M
100.36%
-4.78M
2022Q4
307
29.75M
104.43%
-3.74M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Baker Bros. Advisors LP
4.10M
11.91%
+1.91K
+0.05%
Mar 31, 2025
T. Rowe Price Associates, Inc.
3.50M
10.18%
-369.20K
-9.54%
Dec 31, 2024
Invus Public Equities Advisors, LLC
3.33M
9.68%
--
--
Dec 31, 2024
Redmile Group, LLC
2.95M
8.58%
-120.35K
-3.92%
Dec 31, 2024
Sanofi
1.44M
4.18%
+1.44M
--
Dec 31, 2024
Goldman Sachs & Company, Inc.
965.88K
2.81%
-279.57K
-22.45%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
952.96K
2.77%
+138.07K
+16.94%
Dec 31, 2024
The Vanguard Group, Inc.
896.35K
2.61%
+6.15K
+0.69%
Dec 31, 2024
Fidelity Management & Research Company LLC
473.43K
1.38%
-346.10K
-42.23%
Dec 31, 2024
State Street Global Advisors (US)
459.45K
1.34%
-10.34K
-2.20%
Dec 31, 2024
查看更多
持股ETF
更新时间: 4月6日 周日
更新时间: 4月6日 周日
机构名称
占比
Range Cancer Immunotherapy ETF
0.15%
Virtus LifeSci Biotech Clinical Trials ETF
0.15%
Invesco NASDAQ Future Gen 200 ETF
0.07%
Global X Russell 2000 ETF
0%
Fidelity MSCI Health Care Index ETF
0%
iShares Russell 3000 ETF
0%
iShares Russell 2000 Value ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
JPMorgan BetaBuilders US Small Cap Equity ETF
0%
ProShares Hedge Replication ETF
0%
查看更多
Range Cancer Immunotherapy ETF
占比0.15%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.15%
Invesco NASDAQ Future Gen 200 ETF
占比0.07%
Global X Russell 2000 ETF
占比0%
Fidelity MSCI Health Care Index ETF
占比0%
iShares Russell 3000 ETF
占比0%
iShares Russell 2000 Value ETF
占比0%
DFA Dimensional US Core Equity Market ETF
占比0%
JPMorgan BetaBuilders US Small Cap Equity ETF
占比0%
ProShares Hedge Replication ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据